Last reviewed · How we verify
NCT05032040
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Phase 2 trial testing vudalimab in Ovarian Cancer in 170 participants. Participants enrolled and being followed up; not accepting new ones.
15 October 2025
Quick facts
| Lead sponsor | Xencor, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 170 |
| Start date | 21 July 2022 |
| Primary completion | 15 October 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 17 locations across United States |
Drugs / interventions tested
- vudalimab — full drug profile →
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Clear Cell Carcinoma — all drugs for Clear Cell Carcinoma →
- Endometrial Cancer — all drugs for Endometrial Cancer →
- Cervical Carcinoma — all drugs for Cervical Carcinoma →
Sponsor
Xencor, Inc. — full company profile →
Who can join
18 and older, any sex, with Ovarian Cancer or Clear Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.
Palecki J, Bhasin A, Bernstein A, Mille PJ, et al · · 2024 · cited 25× · PMID 38801069 · DOI 10.1080/15384047.2024.2356820 -
Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question.
Ordóñez-Reyes C, Garcia-Robledo JE, Chamorro DF, Mosquera A, et al · · 2022 · cited 22× · PMID 35745815 · DOI 10.3390/pharmaceutics14061243 -
Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors.
Gu Y, Zhao Q. · · 2024 · cited 16× · PMID 39172329 · DOI 10.1007/s40291-024-00734-w -
Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.
Hushmandi K, Einollahi B, Lee EHC, Sakaizawa R, et al · · 2025 · cited 7× · PMID 39990653 · DOI 10.7150/ijbs.96155 -
TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment.
Pruitt MR, Fabian KP, Lee JM, Hodge JW. · · 2025 · cited 2× · PMID 41201455 · DOI 10.1158/2326-6066.cir-25-0438 -
T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer.
Greiner SM, Mauermann J, Lutz MS, Hagelstein I, et al · · 2025 · cited 1× · PMID 40707958 · DOI 10.1186/s12967-025-06825-4 -
Comprehensive overview of antibody drug-related clinical studies in gynecology: insights from ClinicalTrials.gov.
Zhou X, Xiao L, Lai F, Chen W, et al · · 2025 · cited 1× · PMID 40417700 · DOI 10.3389/fmed.2025.1521587 -
Immunotherapeutic Strategies for Prostate Cancer: A Comprehensive Review.
Flores-Islas AK, Rico-Fuentes C, Sierra-Díaz E, García-Chagollán M, et al · · 2026 · PMID 41595174 · DOI 10.3390/cancers18020255
Verify or expand the search:
- PubMed search for NCT05032040
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Xencor, Inc. trials
Trials by the same sponsor.
- NCT06173505 — Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced N · Phase 1, PHASE2 · terminated
- NCT05996445 — A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors · Phase 1 · terminated
- NCT05585034 — Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Adva · Phase 1 · completed
- NCT06005792 — Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis · Phase 1 · terminated
- NCT05328102 — Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05032040 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xencor, Inc.
- Last refreshed: 7 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05032040.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing